AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
AstraZeneca has launched a Phase III clinical study titled A Multicenter, Parallel-group, Double-blind, 2-Arm, Phase III Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis). The study aims to assess the effectiveness and safety of anifrolumab, a subcutaneous injection, in treating moderate to severe idiopathic inflammatory myopathies, specifically polymyositis and dermatomyositis, alongside standard care.
The intervention being tested is anifrolumab, administered as a weekly subcutaneous injection. It is designed to improve disease activity in patients with idiopathic inflammatory myopathies by being added to the standard care regimen.
This study is interventional, with participants randomly assigned to either the anifrolumab or placebo group. It follows a parallel model and is quadruple-masked, meaning that the participant, care provider, investigator, and outcomes assessor are unaware of the group assignments. The primary goal is treatment-focused.
The study began on June 20, 2024, with its primary completion and estimated study completion dates yet to be announced. The last update was submitted on June 30, 2025, indicating ongoing recruitment and data collection.
For investors, this study represents a significant step for AstraZeneca in expanding its portfolio in the autoimmune disease market. Positive results could enhance AstraZeneca’s market position and influence stock performance favorably. However, competition in the autoimmune treatment sector remains fierce, with several companies pursuing similar advancements.
The study is currently recruiting, with further details available on the ClinicalTrials portal.